EUVIMEDEUVIMED entdecken
Beobachtungsstudie

Pharmacist's role in the management of drug–drug interactions caused by nirmatrelvir/ritonavir in COVID-19 oncohematology patients

Carlos Guzmán Cordero iD, María Sáez-Torres de Vicente, Álvaro Jiménez Espinosa, Ana Isabel Gago Sánchez

Journal of Oncology Pharmacy Practice · 2025

DOI: 10.1177/10781552241237750 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Journal of Oncology Pharmacy Practice, 2025. Verfasst von Carlos Guzmán Cordero und 3 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacy Department, Reina Sofía University Hospital / Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC) / University of Córdoba, C…. Hauptthemen laut MEDLINE: Ritonavir, Pharmacists, COVID-19 Drug Treatment, Professional Role. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 19 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

New drugs developed for SARS-CoV-2 infection, such as nirmatrelvir/ritonavir (NMV/r), represent a potential for oncohematology patients, but also pose a challenge in managing the potential clinically relevant drug–drug interactions (pDDIs) that may arise. The aim of this study is to assess the frequency, severity, and pharmacist detection of pDDIs.

Methods

This prospective, observational, study spanned 8 months, involving 42 oncohematology patients prescribed NMV/r in a tertiary-level hospital. A Board Certified oncology pharmacist assessed pDDIs using three databases and made recommendations to prescribing physicians. Linear and logistic regression analyses were employed to explore the relationship between prescribed drugs and pDDIs.

Results

Clinically relevant pDDIs were detected in 76.2% of patients, with 18.1% of all medications involved in drug–drug interactions (DDIs). The most common drugs implicated were atorvastatin and imatinib. Micromedex® identified 63.3% of interactions as major severity, while Lexicomp® and University of Liverpool classifications were less restrictive. Pharmacists prevented most DDIs from reaching patients through different interventions, including treatment monitoring (44.2%), discontinuation (36.5%), and dose reduction (17.3%).

Conclusion

This study highlights the high prevalence of clinically significant pDDIs in oncohematology patients receiving NMV/r for COVID-19. Pharmacists, as integral members of the healthcare team, played a crucial role in detecting, categorizing, and mitigating these interactions. The results underscore the need for comprehensive studies to evaluate the impact of pharmacist-led interventions in optimizing drug therapy and enhancing patient safety in this vulnerable population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RitonavirPharmacistsCOVID-19 Drug TreatmentProfessional RoleHematologic NeoplasmsAntiviral AgentsHumansDrug InteractionsMaleFemaleMiddle AgedProspective StudiesAgedCOVID-19Adult

Stichwörter der Autor:innen

COVID-19cancer patientsdrug–drug interactionnirmatrelvir/ritonavirpolypharmacy

Substanzen

RitonavirAntiviral Agents

Autor:innen und Institutionen

  • Pharmacy Department, Reina Sofía University Hospital / Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC) / University of Córdoba, Córdoba, Spain.
  • Pharmacy Department, University Clinical Hospital, Valencia, Spain.

ORCID-Profile: Carlos Guzmán Cordero

Zitieren

APA

Guzmán Cordero, C., Sáez-Torres de Vicente, M., Jiménez Espinosa, Á., & Gago Sánchez, A. I. (2025). Pharmacist's role in the management of drug–drug interactions caused by nirmatrelvir/ritonavir in COVID-19 oncohematology patients. Journal of Oncology Pharmacy Practice. https://doi.org/10.1177/10781552241237750

Vancouver

Guzmán Cordero C, Sáez-Torres de Vicente M, Jiménez Espinosa Á, Gago Sánchez AI. Pharmacist's role in the management of drug–drug interactions caused by nirmatrelvir/ritonavir in COVID-19 oncohematology patients. Journal of Oncology Pharmacy Practice. 2025. doi:10.1177/10781552241237750

BibTeX
@article{GuzmnCordero2025,
  author = {Guzmán Cordero, Carlos and Sáez-Torres de Vicente, María and Jiménez Espinosa, Álvaro and Gago Sánchez, Ana Isabel},
  title = {Pharmacist's role in the management of drug–drug interactions caused by nirmatrelvir/ritonavir in COVID-19 oncohematology patients},
  journal = {Journal of Oncology Pharmacy Practice},
  year = {2025},
  doi = {10.1177/10781552241237750}
}
Kostenlos starten →